HK Stock Movement | AKESO (09926) Rises Over 3% Again as FDA Approves Global Phase III Trial for Cadonilimab in First-Line Gastric Cancer Treatment

Stock News12-12

AKESO (09926) surged over 3% again, reaching HK$121.9 by the time of writing, with a trading volume of HK$271 million. The company announced via its official WeChat account that the U.S. Food and Drug Administration (FDA) has approved its global Phase III multicenter clinical trial (COMPASSION-37/AK104-311) for cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The trial will evaluate cadonilimab combined with chemotherapy versus chemotherapy with or without nivolumab as a first-line treatment for HER2-negative unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma.

COMPASSION-37 marks the second international multicenter registrational study for cadonilimab. Previously, a global registrational trial for cadonilimab in immunotherapy-resistant hepatocellular carcinoma had already commenced in the U.S. The approval of COMPASSION-37 represents a critical milestone in AKESO's global development strategy for cadonilimab and reinforces the company's leading position in the field of immuno-oncology 2.0.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment